DSM's development in China enters the third stage

Introduction: DSM group, the "big brother" of global vitamin industry, has officially established its first R & D center in China On the same day, DSM established a joint venture with Zhejiang Shangyu Yuntao Chemical Co., Ltd Jan zuidam, vice chairman of DSM's global board of directors, told reporters that DSM has invested more than $400 million in China In the future, DSM will also accelerate the pace of establishing joint ventures or wholly-owned enterprises in China Jan zuidam, the new expansion movement, did not disclose the amount of investment in the R & D center, but said it would reach several million dollars At the same time, he called the establishment of the R & D center in China the third stage of DSM's development in China "As early as the 1960s, DSM started its technology licensing work in China, which is the first stage of DSM's long-term development in China In the past 10 years, DSM has further increased its investment in China, which is the second stage of its development in China The establishment of DSM China R & D Center marks the third stage of DSM's development in China By setting up R & D centers in China, we will work more closely with the Chinese scientific and technological community, so as to integrate into the development of China's local industries " Jan zuidam explains "DSM China R & D center is an important part of DSM global R & D network," Li Xuedai, sales director of DSM (China) Co., Ltd., told reporters In addition to product and production research and development, the center is also responsible for in-depth tracking of market trends, and extensive exchanges with external academic institutions such as universities, scientific research institutions and industry partners, so as to provide technical support for DSM business development " Jan zuidam said that the R & D center will first meet the needs of product R & D in the Chinese market, "that is, to develop products with Chinese characteristics, which will also be sold to the European and North American markets." According to Jan zuidam, this research and development center mainly researches on the field of vitamin addition intermediates and nutrition, seeks the best production plan through improving the process and process, and will look for the relationship between vitamin and vitamin from the perspective of gene In addition, DSM has invested 36 million yuan to set up a joint laboratory with Fudan University for 20 scientists to carry out scientific research, which will be another part of DSM's R & D business in China this month "DSM's establishment of R & D center in China will play a positive role in improving the level of Vitamin Industry in China In addition, it also reflects DSM's trust in China's intellectual property protection At present, although many foreign-funded enterprises have established R & D centers in China, it seems that there are no pharmaceutical enterprises involved in nutrition " Another vice president of API enterprise, who asked not to be named, said: it is good for us to establish R & D center, because more local technicians will be used to establish R & D center in China, so as to improve the R & D means of API in China Deretil, a subsidiary of DSM, a joint venture established in Zhejiang Province, is a global leader in the R & D, production and sales of β - lactam antibiotic side chains This time, it finally established a joint venture with Shangyu Yuntao Chemical Co., Ltd of China It is reported that the joint venture will be committed to the production of mixed phenylglycine and l-phenylglycine Among them, DSM deretil holds 51% shares and has the right to acquire the remaining 49% shares in the next three years "Through this joint venture, we can combine DSM deretil's technology with the low-cost advantages of Chinese manufacturers," said Lluis franquesa, general manager of DSM deretil "China plays an extremely important role in the field of antibiotic production," said Lluis franquesa "The establishment of a joint venture can reflect DSM's determination to continue to lead the industry." Zhu Yuntao, founder of Shangyu Yuntao Chemical Co., Ltd., told reporters: "Shangyu Yuntao is the largest domestic enterprise producing phenylglycine Cooperation with DSM will help to introduce advanced technology and management experience from abroad." According to Zhu Yuntao, "Shangyu Yuntao company invested 30 million yuan when it was founded, and this transfer of 51% of the shares obtained 40 million yuan." "Although our company never worries about sales, it's too tired to do chemical engineering, so we can't exclude the possibility of transferring the remaining 49% shares in the future," he added DSM's cooperation with Shangyu Yuntao will enable Chinese enterprises to make better use of international channel resources and market resources, an industry insider said A deputy general manager of API enterprise said in an interview that phenylglycine is the main raw material for semi synthetic antibiotics After DSM, a major manufacturer of antibiotics, eats Shangyu, it will greatly reduce its cost, instead of purchasing from several enterprises in the past As we all know, DSM has been looking forward to working with Huabei pharmaceutical for the future "Although there are some difficulties and slow progress in the negotiation of taking shares in Huabei pharmaceutical, it does not mean that we will give up the cooperation with Huayao." In view of DSM's delay in acquiring shares in Sinopharm in recent days, Xia Defan, President of DSM China Co., Ltd., gives such an explanation Xia Defan said that according to past experience, the negotiation always takes a long time, and the negotiation also involves the transfer of listed companies and state-owned shares, which requires a lot of procedures, so the negotiation takes a long time In addition, DSM will discuss the establishment of a joint venture with Sinopharm in the next step